Introduction
Heart failure with preserved ejection fraction (HFpEF) is a frequent disease with a prevalence of 1.1-5.5% in the general population in Europe [1] . From a pathophysiological point of view, symptoms and a prognosis may depend on lack of stroke volume reserve and/or elevated pulmonary artery pressure [2, 3] . In fact, it was shown that left atrial pressure as a major determinant of pulmonary venous and pulmonary artery pressure correlates with symptoms and prognosis [4] . Accordingly, reduction of left atrial pressure may be a promising therapeutic strategy. Consequently, devices have been developed to reduce left atrial pressure through creation of a shunt between the left and right atria [5, 6] . While the V-Wave device (V-Wave. Caesarea, Israel)
CARDIOVASCULAR MEDICINE -KARDIOVASKULÄRE MEDIZIN -MÉDECINE CARDIOVASCULAIRE 2018;21(7-8): [191] [192] [193] [194] has been studied in a small number of patients with HFrEF (heart failure with reduced ejection fraction), the Corvia-device (IASD, Corvia Medical Inc., Tewksbury, MA, USA) has been evaluated in a larger number of patients with HFpEF and HFmrEF (heart failure with mid-range ejection fraction).
Findings
In the REDUCE LAP-HF-Trial, the IASD was studied in 64 patients with HFpEF and HFmrEF in a multicentre, open-label, single-arm, phase I trial [5] . Patients were included if they had evidence of functional class II, III or IV heart failure, an ejection fraction ≥40% and a pulmonary capillary wedge pressure (PCWP) ≥15 mm Hg at rest or ≥25 mm Hg during supine bike exercise. Reducing pulmonary artery pressure with the IASD may be a new therapeutic option to treat symptomatic heart failure patients with preserved or moderately reduced ejection fraction.
As a prerequisite for a left atrial to right atrial pressure gradient on the one hand, and to exclude right ventricular failure on the other, central venous pressure (CVP) had to be lower than 14 mm Hg, and tricuspid annular plain systolic excursion (TAPSE) had to be above 14 mm.
Patients had an average age of 69 years, 66% were female, 72% were in New York Heart Association class III, 81% suffered from hypertension and 33% from diabe- treatment group compared with the control group, although the differences did not achieve statistical significance as the trial was not powered to demonstrate effectiveness in these endpoints [7] . 
Discussion
The studies show that the IASD is safe, reduces PCWP and functions properly through 12 months of follow- The data available from the IASD studies support the hypothesis that elevated left atrial pressure (as indicated by PCWP) inducing post-capillary pulmonary hypertension significantly contributes to the symptoms of patients with "diastolic heart failure" and that reducing left atrial pressure may represent a new therapeutic approach in these patients. This conclusion is consistent with previous work indicating that pulmonary artery pressure is of key pathophysiological relevance in patients with HFpEF [9] . Moreover, there is considerable evidence that pulmonary artery pressures are predictors of mortality in these patients [4, 10] .
Pulmonary artery pressure can be reduced by vasodilators and diuretics, and it has been shown that medical therapy guided by pressure monitoring reduces heart failure hospitalisation, whereas no other therapeutic approach (with the exception of exercise training) has yet shown to be effective in this group of patients [9] . These data, together with the available date Finally, the haemodynamic findings support previous recommendations that HFpEF (or HFmrEF) may require haemodynamic testing during exercise [2, 11] . In all IASD-studies, 30% of patients would not have met the inclusion criteria at rest, but showed clearly elevated pulmonary artery pressures during exercise.
In conclusion, reducing pulmonary artery pressure with the IASD may be a new therapeutic option to treat symptomatic HFpEF and HFmrEF patients.
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